Huitfeldt B, Montgomery S A
Acta Psychiatr Scand Suppl. 1983;308:55-69. doi: 10.1111/j.1600-0447.1983.tb11103.x.
The similarities and differences in the clinical response and incidence of adverse symptoms between zimeldine and amitriptyline have been evaluated by use of a combined analysis of four double-blind clinical trials in depression. In total, 197 patients were included in this series of studies. The efficacy of the drugs was assessed using the Hamilton Rating Scale for Depression (HAM-D). Reports of adverse symptoms were actively elicited by use of a check-list of symptoms and rated for severity. The overall clinical efficacy of the two drugs was shown to be equivalent with a high degree of statistical confidence. However, there exist differences in the profile of action. Amitriptyline has a significant advantage in insomnia problems. In spite of this zimeldine was shown to be at least as effective as amitriptyline in reducing anxiety. Amitriptyline is associated with significantly more anticholinergic side-effects, whereas headache is more disturbing during zimeldine treatment. The combination of several independent trials based on similar protocols can be a useful tool to increase the statistical reliability of conclusions relative to that which can be achieved in standard sized, individual studies in depression.
通过对四项抑郁症双盲临床试验进行综合分析,评估了齐美利定和阿米替林在临床反应及不良症状发生率方面的异同。该系列研究共纳入197例患者。使用汉密尔顿抑郁评定量表(HAM-D)评估药物疗效。通过症状检查表主动收集不良症状报告,并对严重程度进行评分。两种药物的总体临床疗效经高度统计学置信度验证显示相当。然而,它们的作用特点存在差异。阿米替林在解决失眠问题上具有显著优势。尽管如此,齐美利定在减轻焦虑方面至少与阿米替林同样有效。阿米替林伴有明显更多的抗胆碱能副作用,而在齐美利定治疗期间头痛更令人困扰。基于相似方案的多项独立试验相结合,相对于标准规模的抑郁症个体研究而言,可成为提高结论统计可靠性的有用工具。